According to a report by the Financial Times on October 26, 2026, despite the successive shutdowns of two startups, Bootstrap Bio and Manhattan Genomics, commercialization attempts in human embryo gene editing have not ceased. Companies like Preventive have secured nearly $30 million in funding from investors including OpenAI CEO Sam Altman, continuing to advance research on embryo editing technologies. These companies claim their goal is to prevent genetic diseases, but some supporters envision using the technology to influence traits like intelligence, sparking scientific and ethical controversies. Critics worry that commercialization could shift from treating diseases to 'designing' desired traits, exacerbating social inequality. While many countries globally prohibit germline gene editing for reproductive purposes, regulatory uncertainties persist, and the commercialization of the technology faces multiple challenges including ethics, law, and public acceptance.